ORIGINAL ARTICLE

Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing

E Kay¹, A O’Grady¹, J M Morgan², S Wozniak², B Jasani²

¹ Department of Pathology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland
² Department of Histopathology, University Hospital of Wales and College of Medicine, Cardiff CF4 4XN, UK

Correspondence to:
Correspondence to:
Professor E Kay
Department of Pathology, Beaumont Hospital, Dublin 9, Ireland; mleader{at}iol.ie

Aims: To evaluate the use of tissue microarray (TMA) technology as a validation tool for HER2 testing by both immunocytochemistry (ICC) and fluorescence in situ hybridisation (FISH) in the diagnostic setting.

Methods: TMA constructs from 57 cases of breast cancer were evaluated for HER2 (by ICC and FISH) by two centres. The results were compared.

Results: There was a high level of concordance for both ICC and FISH. In five "discrepant" cases only three would have had a potential impact on patient management.

Conclusions: Validation of HER2 analysis in the clinical setting by ICC and FISH is essential. The use of TMAs provides for an economy of scale and would be practical in the setting of interlaboratory and intralaboratory validation. It is suggested that routine HER2 ICC and FISH should continue to be performed in laboratories on whole sections. Following this, TMAs would be constructed for all cases of breast cancer. ICC and FISH would be performed on these to validate the results. The TMAs would be available for circulation to other centres for validation purposes. The standardisation of testing between centres, the potential difficulty of minimum case numbers, and the workload issues surrounding validation would all be facilitated by this approach.

Abbreviations: ICC, immunocytochemistry; FISH, fluorescence in situ hybridisation; NEQAS, National External Quality Assurance Scheme; RCSI, Royal College of Surgeons in Ireland; TMA, tissue microarray

Keywords: HER2; immunocytochemistry; fluorescence in situ hybridisation; validation

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Walker, R A, Bartlett, J M S, Dowsett, M, Ellis, I O, Hanby, A M, Jasani, B, Miller, K, Pinder, S E (2008). HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 61: 818-824 [Abstract] [Full Text]  
• Henriksen, K. L, Rasmussen, B. B, Lykkesfeldt, A. E, Moller, S., Ejlertsen, B., Mouridsen, H. T (2007). Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J. Clin. Pathol. 60: 397-404 [Abstract] [Full Text]  
• Xian, Z-H, Zhang, S-H, Cong, W-M, Wu, W-Q, Wu, M-C (2005). Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J. Clin. Pathol. 58: 500-503 [Abstract] [Full Text]